Encrypted login | home

Program Information

Validation of ELP Dosimetry Using PRESAGE Dosimeter: Feasibility Test and Practical Considerations

no image available
K Lambson

K Lambson1*, K Lafata1 , J Schaal3 , D Miles1 , S Yoon1 , W Liu3 , M Oldham1,2 , J Cai1,2 , (1) Duke University Medical Physics Program, Durham, NC, (2) Duke University Medical Center, Radiation Oncology, Durham, NC, (3) Duke University Department of Biomedical Engineering, Durham, NC,


SU-F-T-10 (Sunday, July 31, 2016) 3:00 PM - 6:00 PM Room: Exhibit Hall


To validate the use of a PRESAGE dosimeter as a method to quantitatively measure dose distributions of injectable brachytherapy based on elastin-like polypeptide (ELP) nanoparticles. PRESAGE is a solid, transparent polyurethane-based dosimeter whose dose is proportional to a change in optical density, making it useful for visualizing the dose from a radionuclide-tagged-ELP injection.


A PRESAGE dosimeter was designed to simulate an ELP injection. To calibrate, cuvette samples from the batch of PRESAGE were exposed to varying levels of radiation from 0-35.9Gy applied via a linear accelerator, then placed into a spectrophotometer to obtain the optical density change as a function of dose. A pre-optical-CT scan was acquired of the phantom to obtain a baseline tomographic optical density. A 1cc saline solution of I-125 tagged-ELP with and activity concentration of 1mCi/cc was injected into the phantom and left for five days. After five days, the ELP was removed and the cavity cleaned of all remaining radioactive material. Post tomographic optical images were acquired to obtain a differential optical density dataset.


Initial results after the 5-day exposure revealed an opaque white film that resembled the volume of the ELP solution injected into the phantom. We think this is possibly due to the saline solution diffusing into the PRESAGE and causing a change in the index of refraction at this shallow depth. Therefore, initially the optical scanner yielded inconclusive results. After several more days, the saline seemed to have evaporated out of the injection site and the ELP dose distribution was visible via color change in the dosimeter.


We have created the first experimental design to measure the dose distribution of I-125-tagged-ELP. The PRESAGE formulation proves to be a feasible option for such measurements. Future experimental measurements need to be obtained to further characterize ELP dosimetry.

Contact Email: